Galderma Hopes To Break Into Prurigo Nodularis Market, But May Face Rivals

The dermatology specialist announced positive results from the OLYMPIA 2 trial of nemolizumab, but Sanofi and Regeneron are already pursuing a similar indication for Dupixent. 

Galderma announced results from the Phase III OLYMPIA 2 trial of nemolizumab in prurigo nodularis • Source: Shutterstock

The Swiss dermatology company Galderma S.A. is looking to edge into a niche market for the rare disease prurigo nodularis with nemolizumab, but the company could have to face big pharma rivals in the space. Regeneron Pharmaceuticals, Inc. and Sanofi are roughly three months out from securing another potential indication for their blockbuster autoimmune disease drug Dupixent (dupilumab) for the treatment of prurigo nodularis from the US Food and Drug Administration.

Dupixent is a blockbuster drug marketed by two large pharmaceutical companies, while Galderma is an experienced dermatology player but with...

More from Clinical Trials

More from R&D